Table 2.
GOG Studies stratified by race
| White N=37,617(%) |
Black N= 3,686(%) |
Other N=3,956(%) |
p value | |
|---|---|---|---|---|
| Number of patients | ||||
| Tumor Site | ||||
| Ovary | 23,269 (87%) | 1,258 (5%) | 2,290 (8%) | <0.001 |
| Endometrial | 9,289 (87%) | 850 (8%) | 590 (5%) | <0.001 |
| Cervix | 4,421 (65%) | 1,340 (20%) | 1,038 (15%) | <0.001 |
| Sarcoma | 638 (70%) | 238 (26%) | 38 (4%) | <0.01 |
| Type of Study | ||||
| Phase I | 449 (87%) | 19 (4%) | 47 (9%) | |
| Phase II | 3,277 (85%) | 343 (9%) | 249 (6%) | |
| Phase III | 22,038 (81%) | 2,342 (9%) | 2,865 (10%) | |
| Observational | 5,322 (87%) | 405 (7%) | 376 (6%) | |
| Translational | 4,115 (88%) | 365 (8%) | 210 (4%) | |
| Publication Years | ||||
| ≤ 1993 | 0 (0) | 0 (0) | 0 (0) | |
| 1994 to 2002 | 2,818 (76.0) | 593 (16.0) | 295 (8.0) | |
| 2003 to 2008 | 11,206 (80.2) | 1,483 (10.8) | 1,063 (7.7) | |
| 2009 to 2013 | 23,593 (84.9) | 1,610 (5.8) | 2,598 (9.3) | |